FDA Determines Regulatory Review Period for REBINYN Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially announced its determination of the regulatory review period for REBINYN, a human biological product, in accordance with federal regulations, following a request from the U.S. Patent and Trademark Office (USPTO).